Dion A. Daniels
GlaxoSmithKline
5 Papers
Dion A. Daniels is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Aptamer & Biology. The author has an hindex of 5, co-authored 5 publications.
Chat about Author
Papers
A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment
TL;DR: The interaction of the DNA aptamer, GBI-10, with tenascin-C, an extracellular protein found in the tumor matrix is characterized, believed to be involved in both embryogenesis and oncogenesis pathways.
619
Circadian clock component REV-ERBα controls homeostatic regulation of pulmonary inflammation
Marie Pariollaud,Julie E. Gibbs,Thomas Hopwood,Sheila Brown,Nicola Begley,Ryan Vonslow,Toryn Poolman,Baoqiang Guo,Ben Saer,D. Heulyn Jones,James P. Tellam,Stefano Bresciani,Nicholas C. O. Tomkinson,Justyna Wojno-Picon,Anthony William James Cooper,Dion A. Daniels,Ryan P. Trump,Daniel Grant,Daniel Grant,William J. Zuercher,William J. Zuercher,Timothy M. Willson,Timothy M. Willson,Andrew S. MacDonald,Brian Bolognese,Patricia L. Podolin,Yolanda Sanchez,Andrew S. I. Loudon,David W. Ray +28 more
TL;DR: A novel selective oxazole-based inverse agonist of REV-ERB, which protects REV -ERB&agr; protein from degradation, is developed, and used to reveal how proinflammatory cytokines trigger rapid degradation of REB&bgr; in the elaboration of an inflammatory response.
Identification of Potent and Selective RNA Antagonists of the IFN-γ-Inducible CXCL10 Chemokine†
Martin L Marro,Dion A. Daniels,Anne McNamee,David P. Andrew,Trevor D. Chapman,Ming S Jiang,Zining Wu,Janet L. Smith,Kalpana Patel,Katy L. Gearing +9 more
TL;DR: These aptamers generated are the most potent antagonists of CXCL10/CXCR3 signaling reported to date and could be utilized as powerful target validation tools and may also have therapeutic potential.
30
In vitro selection of RNA aptamers that block CCL1 chemokine function.
TL;DR: In vitro isolation of the first nuclease resistant and selective RNA aptamer (T48) with high-binding affinity for human and mouse CCL1, which constitutes one of the most potent CCR8 antagonists reported to date and is an excellent tool to dissect CCL 1-specific function in vivo.
REVERBa couples the circadian clock to hepatic glucocorticoid action
Giorgio Caratti,Mudassar Iqbal,Louise Hunter,Donghwan Kim,Ping Wang,Ryan Vonslow,Nicola Begley,Abigail J. Tetley,Joanna Woodburn,Marie Pariollaud,Robert Maidstone,Ian J. Donaldson,Zhenguang Zhang,Louise Ince,Gareth B. Kitchen,Matthew Baxter,Toryn Poolman,Dion A. Daniels,David R. Stirling,Chad Brocker,Frank J. Gonzalez,Andrew S. I. Loudon,David A. Bechtold,Magnus Rattray,Laura Matthews,David W. Ray +25 more
TL;DR: It is demonstrated that while antiinflammatory GC actions were maintained irrespective of dosing time, the liver was significantly more GC sensitive during the day, and deletion of Reverba inverted circadian liver GC sensitivity and protected mice from hepatosteatosis induced by chronic GC administration are revealed.